Christopher Alexander

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. ncbi request reprint Clinical utility of testing human immunodeficiency virus for drug resistance
    P R Harrigan
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC, V6Z 1Y6, Canada
    Clin Infect Dis 30:S117-22. 2000
  2. pmc A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance
    P Richard Harrigan
    BC Centre for Excellence in HIV AIDS, 603 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada
    J Virol 76:6836-40. 2002
  3. ncbi request reprint Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease
    Christopher S Alexander
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, British Columbia, Canada
    J Infect Dis 188:541-8. 2003
  4. ncbi request reprint Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy
    P Richard Harrigan
    BC Centre for Excellence in HIV AIDS, Vancouver, BC, Canada
    Antivir Ther 8:395-402. 2003
  5. ncbi request reprint Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, and Department of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 191:339-47. 2005
  6. ncbi request reprint HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Infect Dis 191:1325-30. 2005
  7. ncbi request reprint Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry
    Andrew Volosov
    Children s National Medical Center, Washington, DC, USA
    Clin Biochem 35:99-103. 2002

Detail Information

Publications7

  1. ncbi request reprint Clinical utility of testing human immunodeficiency virus for drug resistance
    P R Harrigan
    British Columbia Centre for Excellence in HIV AIDS, Vancouver, BC, V6Z 1Y6, Canada
    Clin Infect Dis 30:S117-22. 2000
    ..HIV drug-resistance testing is also useful as a tool for new antiretroviral drug design and development, as well as for monitoring the spread of primary HIV drug resistance...
  2. pmc A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance
    P Richard Harrigan
    BC Centre for Excellence in HIV AIDS, 603 1081 Burrard Street, Vancouver, British Columbia V6Z 1Y6, Canada
    J Virol 76:6836-40. 2002
    ..3-, and 84-fold, respectively, as well as >100- and >60-fold decreases in delavirdine and nevirapine susceptibility, respectively. These results indicate the importance of the Y318F substitution in HIV-1 drug resistance...
  3. ncbi request reprint Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease
    Christopher S Alexander
    British Columbia Centre for Excellence in HIV AIDS, University of British Columbia, Vancouver, British Columbia, Canada
    J Infect Dis 188:541-8. 2003
    ..01). These results may reflect incomplete adherence, since a strong association (P<.001) was found between low drug levels and an imperfect prescription-refill record (<95%)...
  4. ncbi request reprint Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy
    P Richard Harrigan
    BC Centre for Excellence in HIV AIDS, Vancouver, BC, Canada
    Antivir Ther 8:395-402. 2003
    ....
  5. ncbi request reprint Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, and Department of Medicine, University of British Columbia, Vancouver, Canada
    J Infect Dis 191:339-47. 2005
    ....
  6. ncbi request reprint HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach
    P Richard Harrigan
    British Columbia Centre for Excellence in HIV AIDS, St Paul s Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Infect Dis 191:1325-30. 2005
    ..Our results suggest that analysis of a combined historical genotype rather than of a cross-sectional genotype may lead to more accurate estimates of antiretroviral drug resistance in individual patients and in patient populations...
  7. ncbi request reprint Simple rapid method for quantification of antiretrovirals by liquid chromatography-tandem mass-spectrometry
    Andrew Volosov
    Children s National Medical Center, Washington, DC, USA
    Clin Biochem 35:99-103. 2002
    ....